Drug Profile
Research programme: human therapeutic antibodies - Medarex/Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Medarex; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Bacterial infections; Cancer; Inflammation; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA